Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya.

Anthony O Etyang ORCID logo; RuthLucinde; HenryKaranja; CatherineKalu; DaisyMugo; JamesNyagwange; JohnGitonga; JamesTuju; PerpetualWanjiku; AngelaKarani; +40 more... ShadrackMutua; HoseaMaroko; EddyNzomo; EricMaitha; EvansonKamuri; ThuraniraKaugiria; JustusWeru; Lucy BOchola; NelsonKilimo; SandeCharo; NamdalaEmukule; WycliffeMoracha; DavidMukabi; RosemaryOkuku; MonicahOgutu; BarrackAngujo; Mark Otiende ORCID logo; Christian Bottomley ORCID logo; EdwardOtieno; LeonardNdwiga; AmekNyaguara; Shirine Voller ORCID logo; Charles NAgoti; David JamesNokes; Lynette IsabellaOchola-Oyier; RashidAman; PatrickAmoth; MercyMwangangi; KadondiKasera; WangariNg'ang'a; Ifedayo MO Adetifa ORCID logo; EWangeci Kagucia; Katherine Gallagher ORCID logo; SophieUyoga; BenjaminTsofa; EdwineBarasa; PhilipBejon; J Anthony G Scott ORCID logo; Ambrose Agweyu ORCID logo; George MWarimwe; (2021) Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 74 (2). pp. 288-293. ISSN 1058-4838 DOI: 10.1093/cid/ciab346
Copy

BACKGROUND: Few studies have assessed the seroprevalence of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among healthcare workers (HCWs) in Africa. We report findings from a survey among HCWs in 3 counties in Kenya. METHODS: We recruited 684 HCWs from Kilifi (rural), Busia (rural), and Nairobi (urban) counties. The serosurvey was conducted between 30 July and 4 December 2020. We tested for immunoglobulin G antibodies to SARS-CoV-2 spike protein, using enzyme-linked immunosorbent assay. Assay sensitivity and specificity were 92.7 (95% CI, 87.9-96.1) and 99.0% (95% CI, 98.1-99.5), respectively. We adjusted prevalence estimates, using bayesian modeling to account for assay performance. RESULTS: The crude overall seroprevalence was 19.7% (135 of 684). After adjustment for assay performance, seroprevalence was 20.8% (95% credible interval, 17.5%-24.4%). Seroprevalence varied significantly (P < .001) by site: 43.8% (95% credible interval, 35.8%-52.2%) in Nairobi, 12.6% (8.8%-17.1%) in Busia and 11.5% (7.2%-17.6%) in Kilifi. In a multivariable model controlling for age, sex, and site, professional cadre was not associated with differences in seroprevalence. CONCLUSION: These initial data demonstrate a high seroprevalence of antibodies to SARS-CoV-2 among HCWs in Kenya. There was significant variation in seroprevalence by region, but not by cadre.



picture_as_pdf
Etyang_etal_2021_Seroprevalence-of-antibodies-to-severe.pdf
subject
Published Version
Available under Creative Commons: 3.0

View Download